Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry.

Vince B C BiemansJasmijn A M SleutjesAnnemarie C de VriesAlexander G L BodelierGerard DijkstraBas OldenburgMark LöwenbergAdriaan A van BodegravenAndrea E van der Meulen-de JongNanne K H de BoerNidhi SrivastavaRachel L WestTessa E H RömkensCarmen S Horjus Talabur HorjeJeroen M JansenC Janneke van der WoudeJildou HoekstraRinse K WeersmaFiona D M van SchaikFrank HoentjenMarieke J Pieriknull null

Published in: Alimentary pharmacology & therapeutics (2020)

Tofacitinib is an effective treatment for UC after anti-TNF and vedolizumab failure. However, a relatively high rate of adverse events was observed resulting in discontinuation in 6% of patients.

Keyphrases

ulcerative colitis
rheumatoid arthritis
end stage renal disease

ejection fraction
newly diagnosed

peritoneal dialysis
quality improvement

patient reported outcomes
patients with inflammatory bowel disease